Literature DB >> 14566382

Probiotics: Isolated bacteria strain or mixtures of different strains? Two different approaches in the use of probiotics as therapeutics.

O Karimi1, A S Pena.   

Abstract

Probiotics are cultures of beneficial bacteria from the healthy gut microflora that improve the balance of the intestinal milieu by modifying the intestinal microflora and suppressing enhanced inflammatory responses. Probiotics are currently the subject of intense and widespread research as functional foods since they are known to induce health benefits, may be used as pharmaceutical preparations, and have achieved a "generally recognized as safe" (GRAS) status. Lactobacillus strains can also be genetically engineered for use in oral immunotherapeutic applications, such as vaccination and delivery of immunoregulatory substances. In the present review we evaluate the two different approaches to the therapeutic use of probiotics. We also focus on recent findings in the field of molecular biology and genetics of the intestinal immune response related to the microflora and intestinal ecology, in order to understand the mechanisms of action of probiotics and their present indications in gastrointestinal diseases. Finally, with a view to future perspectives we provide some examples of probiotics that are being assessed and have great potential in improving the health of animals and man.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14566382     DOI: 10.1358/dot.2003.39.8.799406

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  7 in total

1.  Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats.

Authors:  Hani Al-Salami; Grant Butt; Ian Tucker; Svetlana Golocorbin-Kon; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-08-28       Impact factor: 2.441

2.  Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats.

Authors:  Hani Al-Salami; Grant Butt; Ian Tucker; Ranko Skrbic; Svetlana Golocorbin-Kon; Momir Mikov
Journal:  Arch Drug Inf       Date:  2008-07

3.  Detection of Bifidobacterium animalis subsp. lactis (Bb12) in the intestine after feeding of sows and their piglets.

Authors:  Gloria Solano-Aguilar; Harry Dawson; Marta Restrepo; Kate Andrews; Bryan Vinyard; Joseph F Urban
Journal:  Appl Environ Microbiol       Date:  2008-08-08       Impact factor: 4.792

4.  Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats.

Authors:  Hani Al-Salami; Grant Butt; J Paul Fawcett; Ian G Tucker; Svetlana Golocorbin-Kon; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Apr-Jun       Impact factor: 2.441

Review 5.  Mast Cells in Gut and Brain and Their Potential Role as an Emerging Therapeutic Target for Neural Diseases.

Authors:  Giovanna Traina
Journal:  Front Cell Neurosci       Date:  2019-07-30       Impact factor: 5.505

6.  Bifidobacterium animalis subspecies lactis modulates the local immune response and glucose uptake in the small intestine of juvenile pigs infected with the parasitic nematode Ascaris suum.

Authors:  Gloria Solano-Aguilar; Terez Shea-Donohue; Kathleen B Madden; Alejandro Quinoñes; Ethiopia Beshah; Sukla Lakshman; Yue Xie; Harry Dawson; Joseph F Urban
Journal:  Gut Microbes       Date:  2018-07-19

7.  Probiotics and gastrointestinal disease: successes, problems and future prospects.

Authors:  Eamonn P Culligan; Colin Hill; Roy D Sleator
Journal:  Gut Pathog       Date:  2009-11-23       Impact factor: 4.181

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.